Results 51 to 60 of about 11,898 (160)

Health Literacy and Unmet Needs in Patients With Multiple Sclerosis: A Cross‐Sectional Study

Journal of Clinical Nursing, EarlyView.
ABSTRACT Aims To identify a correlation between unmet needs and HL levels in people with Multiple Sclerosis (pwMS) and to evaluate how sociodemographic characteristics influence HL levels and unmet needs. Design A cross‐sectional study. Methods The study was conducted using a questionnaire including the HLS19‐Q12 to assess HL and the Long‐term Unmet ...
Francesco Pastore, Barbara Forastefano, Valentina Simonetti, Tommaso Guerra, Giancarlo Cicolini, Pietro Iaffaldano, Dania Comparcini   +6 more
wiley   +1 more source

Consenso español actualizado sobre el uso del natalizumab (Tysabri®)-2013

Neurología, 2015
Resumen: Introducción: Natalizumab es un tratamiento que ha demostrado ser muy eficaz en los ensayos clínicos y muy efectivo en la práctica clínica en los pacientes con esclerosis múltiple recurrente-remitente, en cuanto a la reducción del número de ...
O. Fernández, J.A. García-Merino, R. Arroyo, J.C. Álvarez-Cermeño, G. Izquierdo, A. Saiz, J. Olascoaga, A. Rodríguez-Antigüedad, J.M. Prieto, C. Oreja-Guevara, M.A. Hernández, E. Moral, J. Meca, X. Montalbán   +13 more
doaj   +1 more source

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient‐Reported Disability Measure and Self‐Administered Neuroperformance Outcomes

Annals of Neurology, Volume 100, Issue 3, Page 525-546, September 2026.
Objective The objective of this study was to investigate the ability of patient‐reported/administered outcomes to capture disability worsening and progression independent of relapse activity (PIRA) in multiple sclerosis (MS). Methods We included patients from the longitudinal multicenter MS PATHS cohort with ≥3 assessments and >6 months follow‐up. PIRA
Evy M. Reinders, Ariadna Masot‐Llima, Susana Otero‐Romero, René Carvajal, Álvaro Cobo‐Calvo, Pere Carbonell‐Mirabent, Jordina Beltran, Maria Jesús Arévalo, Helena Ariño, Georgina Arrambide, Cristina Auger, Luca Bollo, Joaquín Castilló, Manuel Comabella, Ingrid Galán, Alexis García‐Sarreón, Andrew Goodman, Carrie M. Hersh, Delon La Puma, Le H. Hua, Luciana Midaglia, Neus Mongay‐Ochoa, Ellen M. Mowry, Agustín Pappolla, Breogán Rodríguez‐Acevedo, Jordi Río, Paula Tagliani, Ángela Vidal‐Jordana, Andreu Vilaseca, Ana Zabalza, Deborah Pareto, Carlos Nos, Menno Schoonheim, Eva Strijbis, Jaume Sastre‐Garriga, Madalina Tivarus, Tjalf Ziemssen, Àlex Rovira, Xavier Montalban, Mar Tintoré, Carmen Tur   +40 more
wiley   +1 more source

Comparative Effectiveness Analysis of Phase 3 Clinical Trials in Moderately to Severely Active Inflammatory Bowel Disease Reveals Increased Harm From Placebo and Challenges Equipoise

JCC Plus, Volume 1, Issue 5, September 2026.
Across 47 Phase 3 trials in Crohn's disease and ulcerative colitis, placebo exposure was associated with measurable harm. Disease exacerbation events showed the greatest excess risk, with one additional exacerbation occurring for every 8–13 patients assigned to placebo rather than active therapy.
Joëlle St‐Pierre, Zachary D. Fine, Evan N. Fear, Jeremy A. Klein, Natalie K. Choi, David T. Rubin   +5 more
wiley   +1 more source

Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy (PML).

Frontiers in Neurology, 2013
Natalizumab (Tysabri®) is a monoclonal antibody that prevents inflammatory cells from binding to brain endothelial cells and passing into the brain parenchyma.
Hans eLindå, Anders evon Heijne
doaj   +1 more source

Inflammatory Bowel Disease: Mechanisms and Therapeutic Advances

MedComm, Volume 7, Issue 9, September 2026.
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a rising, multifactorial chronic disorder driven by dysregulated mucosal immunity in genetically susceptible individuals and influenced by environmental and microbial factors.
Andrea Papait, Anna Cargnoni, Franco Scaldaferri, Loris Lopetuso, Antonietta Rosa Silini, Ornella Parolini   +5 more
wiley   +1 more source

Characterizing Combined Central and Peripheral Demyelination—Insights From a Multimodal Comparison With Chronic Inflammatory Demyelinating Polyneuropathy and Multiple Sclerosis

Muscle &Nerve, Volume 74, Issue 3, Page 605-615, September 2026.
ABSTRACT Introduction/Aims Combined central and peripheral demyelination (CCPD) is a rare dysimmune disorder sharing features with multiple sclerosis (MS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Direct comparisons of central and peripheral diagnostic findings across these entities remain limited. We, therefore, performed a
N. Dubuisson, A. Kassab, P. Y. K. Van den Bergh, A. F. J. E. Vrancken, W. L. van der Pol, L. H. van den Berg, H. S. Goedee   +6 more
wiley   +1 more source

Review: Natalizumab in the treatment of multiple sclerosis

Therapeutic Advances in Neurological Disorders, 2009
Natalizumab reduced the rate of clinical relapse at one year by 68% and the risk of sustained progression of disability by 42—54% over 2 years in its pivotal phase III trial (AFFIRM) in relapsing—remitting multiple sclerosis (RRMS).
Özgür Yaldizli, Norman Putzki
doaj   +1 more source

The Neurovascular Niche: A Gathering Venue for Neuroinflammation and Remyelination in Multiple Sclerosis

Acta Physiologica, Volume 242, Issue 9, September 2026.
ABSTRACT In the central nervous system (CNS), the tissue microenvironment is continuously monitored and regulated to secure the unobstructed function of neurons and of their networks. This is a key function of the neurovascular niche (NVN), which is the interface between the cells of the nervous tissue and the cells and the content of blood vessels. It
Ilias Kazanis, Maria Elena Silva, Alerie G. de la Fuente, Fernando de Castro, Francisco J. Rivera   +4 more
wiley   +1 more source

Targeting progressive multiple sclerosis: Toward mechanism‐informed precision medicine

Journal of Internal Medicine, Volume 300, Issue 3, Page 238-257, September 2026.
Abstract Multiple sclerosis has undergone a therapeutic revolution over the past three decades. Randomized clinical trials and real‐world data demonstrate that modern disease‐modifying therapies substantially reduce relapse rates and acute inflammatory activity detected by magnetic resonance imaging (MRI).
Fredrik Piehl, Gonçalo Castelo‐Branco, Maja Jagodic, Tomas Olsson   +3 more
wiley   +1 more source